Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 108; no. 5; pp. 1442 - 1446
Main Authors Knörr, Fabian, Schellekens, Kim P.J., Schoot, Reineke A., Landman-Parker, Judith, Teltschik, Heiko-Manuel, Förster, Jan, Riquelme, Amambay, Huitema, Alwin D.R., Van Eijkelenburg, Natasha K.A., Beishuizen, Auke, Zwaan, C. Michel, Woessmann, Wilhelm, Van der Lugt, Jasper
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.05.2023
Ferrata Storti Foundation
Subjects
Anaplastic Lymphoma Kinase
Child
Crizotinib
Humans
Letter to the Editor
Lymphoma, Large-Cell, Anaplastic - pathology
Receptor Protein-Tyrosine Kinases
Vinblastine
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
KS, RS, AH, NvE, CMZ, AB and JvdL received institutional funding from Pfizer. FK, HT, AR, JF, JLP and WW have no conflicts of interest to declare.
Disclosures
FK and KS collected and analyzed the data, and wrote the first draft of the manuscript; HT and JLP provided patient data; AR, JF and NE collected patient data; AB, CMZ, AH, JvdL and WW were involved in the conceptualization and study design of Stratum I of the CRISP trial; JvdL, RS and WW supervised the analyses; all authors reviewed and revised the manuscript, and approved the final version for submission.
Contributions
Individual patient data that underlie the results reported in this article will be made available in deidentified form to researchers who provide a methodologically sound proposal for data usage. Proposals should be directed to the corresponding author.
Data-sharing statement
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2022.281896